Currenc Group Inc Stock Price, News & Analysis

Avenir Wellness Solutions (OTCQB:CURR) announced the launch of an informational series focused on its unique dual revenue model, highlighting breakthrough consumer wellness products and intellectual property (IP) monetization. In collaboration with New to The Street, the company aims to enhance its visibility through televised content featuring its leadership. CEO Nancy Duitch emphasized the company's innovative delivery technologies and its 15 patents in the wellness sector. This initiative is expected to increase Avenir's market share in a multi-billion-dollar industry, showcasing its commitment to growth and the advancement of its proprietary wellness solutions.

Avenir Wellness Solutions, Inc. (formerly CURE Pharmaceutical Holding Corp.) announced its corporate name change on January 17, 2023, following the sale of certain intellectual property. This rebranding aims to reflect a renewed focus on developing innovative wellness technologies in the beauty sector. The company plans to enhance shareholder value through an incubator strategy, expanding its patent portfolio, and leveraging partnerships with social media influencers. Avenir targets high-margin markets, including the $587.3 billion supplements industry, emphasizing its proprietary delivery systems to improve product efficacy and consumer experience.

CURE Pharmaceutical Holding Corp. (CURR) shares positive developments following its asset sale in July 2022. The company focuses on innovative wellness and beauty products, planning to enhance its market presence through strategic partnerships and influencer marketing, including collaboration with Nicole Kidman. Notable achievements include a 32.1% year-over-year revenue increase in Q3 2022, reaching $1.8 million, with gross margins improving to 80%. With a strong patent portfolio and new products launching in the first half of 2023, CURE is poised for growth in a booming wellness market projected to exceed $450 billion.

CURE Pharmaceutical Holding Corp. (OTCQB:CURR) reported a 32.1% year-over-year revenue increase in Q3 2022, reaching $1.8 million, with expectations of further growth in Q4. Gross margins improved to 80.0%, reflecting effective marketing initiatives. The company reduced SG&A expenses by $0.1 million and narrowed operating losses despite increasing marketing investments. A $20 million asset sale earlier this year enhanced their cash position, supporting future growth in innovative wellness solutions and marketing campaigns.

CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a 31.2% increase in gross revenue, reaching $1.6 million for Q2 2022. The company successfully sold $20 million in assets, bolstering its cash position and reducing debt. SG&A expenses decreased by $3.4 million, while operating loss narrowed by $1.0 million. New marketing programs are yielding positive early results, with sales from the Seratopical skincare line ramping up in Walmart stores. Key appointments to the board enhance governance and strategic direction. CURE aims to accelerate high-margin sales and shareholder value initiatives.

CURE Pharmaceutical has appointed Rob Davidson as Chairman of the Board and Robert J. Costantino to the board, enhancing leadership with extensive financial experience. Davidson, a former CEO, will focus on product development and non-dilutive transactions, while Costantino brings decades of experience from previous leadership roles in financial operations. These changes aim to bolster shareholder value and support ongoing initiatives for growth, especially for the subsidiary The Sera Labs. The company emphasizes continuity and commitment to investors.

On August 3, 2022, CURE Pharmaceutical Holding Corp. (OTC: CURR) hosted a shareholder call to discuss a recent $20 million non-dilutive sale of part of its product and intellectual property portfolio. The executive team outlined their strategy to innovate and monetize their technology while building The Sera Labs brands to enhance shareholder value. The call's replay will be available until August 3, 2023. CURE is known for its patented drug delivery platform, CUREform™, which aims to improve drug efficacy and patient experience.

CURE Pharmaceutical has appointed Gerald Bagg to its board of directors, enhancing its expertise in the consumer packaged goods (CPG) and advertising sectors. Bagg, a 45-year veteran in advertising, aims to leverage his experience to bolster the company's branding efforts and drive growth for its subsidiary, The Sera Labs, Inc., which focuses on wellness and beauty products. This move increases the board's membership to five, aligning with CURE's strategy to develop and acquire innovative brands.

CURE Pharmaceutical Holding Corp. (OTC: CURR) announces a teleconference on August 3, 2022, to discuss a recent $20 million non-dilutive sale of part of its product and IP portfolio. The company retains exclusive rights to its Nutraceutical Nutri-Strip products and is pursuing international transactions to monetize its extensive patent portfolio, which includes areas like CBD and psychedelics. CURE's subsidiary, The Sera Labs, plans to relaunch its Seratopical Revolution line, recently supplied to over 1,200 Walmart stores, as part of its strategy to enhance shareholder value.